NCT02414932View on ClinicalTrials.gov

Ketamine for Depression Relapse Prevention Following ECT

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

April 7, 2017

Study Completion Date

April 7, 2017

Conditions
Depression
Interventions
DRUG

Ketamine

Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland

DRUG

Midazolam

Midazolam 0.045 mg/kg; Roche Products Ireland Ltd

Trial Locations (1)

8

St Patrick's University Hospital, Dublin

All Listed Sponsors
collaborator

Health Research Board, Ireland

OTHER

lead

St Patrick's Hospital, Ireland

OTHER

NCT02414932 - Ketamine for Depression Relapse Prevention Following ECT | Biotech Hunter | Biotech Hunter